Safety and Biological Efficacy Study of TisssueGene-C to Degenerative Arthritis
A Dose-escalating, Single-center, Phase I Clinical Trial to Investigate the Safety and Biological Efficacy of TissueGene-C in Degenerative Arthritis Patients.
The primary purpose of the this study is to evaluate the safety of TissueGene-C, a gene therapy product that uses allogenic human chondrocytes expressing Transforming Growth Factor(TGF)-β1 by assessing the inflammation at the injection site, the incidence and severity of the adverse events, the physical examination findings, and the laboratory test results after the intra-articular injection of TissueGene-C.
And Secondary purpose is to evaluate the biological efficacy (knee pain, range of motion, functional tests, and MRI) of TissueGene-C and the distribution of TissueGene-C outside the injection site.
연구 개요
상태
정황
상세 설명
TissueGene-C is a biological new drug which consists of normal chondrocyte cells and transduced chondrocyte cells that express growth factor to modify osteoarthritis symptom for long term period.
During clinical trial Phase 1, we compare three different dose levels of TisssueGene-C in 6 months with 12 outpatients with degenerative arthritis. The patients are randomized by three different dose levels of TisssueGene-C in 1:1:1 ratio, and they are monitored and recorded for alleviating symptoms, sports activities, function of the knee, and the presence of adverse events.
연구 유형
등록 (실제)
단계
- 1단계
연락처 및 위치
연구 장소
-
-
-
Seoul, 대한민국, 135-710
- Samsung Medical Center
-
-
참여기준
자격 기준
공부할 수 있는 나이
건강한 자원 봉사자를 받아들입니다
연구 대상 성별
설명
Inclusion Criteria:
- Male or female patients
- Patients aged 45 years or more with Grade IV [based on the International Cartilage Repair Society(ICRS) evaluation criteria from the MRI scan results] degenerative arthritis of the knee, whose symptoms had not been relieved by the conventional symptomatic treatment
- Healthy, with no major physical examination, hematology, serum chemistry, and urine test findings and no significant medical history
- Patients with cartilage damage sized 2-6 cm2 (based on the ICRS evaluation criteria from the MRI scan results)
- Voluntarily agreed to participate in this study and signed the informed consent form
Exclusion Criteria:
- Showed clinically significant hematology, serum chemistry, or urine test results at the screening visit
- Took an anti-inflammatory medication (prescribed or over-the-counter), including natural medicine, within 14 days from the administration of the investigational product
- Has a history of drug abuse within one year from the enrollment, or the urine test or blood alcohol test result was positive at the screening visit
- Received any injection in the target knee within two months before the initiation of the study
- Pregnant or breastfeeding female
- With another joint disease apart from degenerative arthritis (e.g., systemic rheumatic inflammatory disease associated with the knee or chondrocalcinosis, hemachromatosis, inflammatory arthritis, necrosis of the trochanter, Paget's disease adjacent to a joint in the femur or the tibia, ochronosis, hemophilic arthropathy, infectious arthritis, Charcot's disease in the knee joint, villonodular synovitis, and synovial chondromas)
- With an infectious disease, including HIV or hepatitis (HBV/HCV)
With a history any of the following clinically significant diseases:
- heart disease [e.g., myocardial infarction, arrhythmia, other serious heart disease, coronary artery bypass graft (CABG)]
- kidney disease (e.g., chronic renal failure, glomerulonephritis)
- liver disease (e.g., liver cirrhosis, fatty liver, acute or chronic liver disease)
- endocrine disease (e.g., hyperthyroidism, hypothyroidism, thyroiditis, diabetes insipidus, Cushing's disease)
- insulin-dependent diabetes mellitus
medical history of or current malignant tumor In particular, the tumors that TissueGene-C may aggravate can be screened using the following tests
- Leukemia : White Blood Cell level in the hematology
- Osteochondroma, Chondromas, Chondroblastoma, Chondromyxoid fibroma, Chondrosarcoma : Alkaline phosphatase level in the hematology
- Participated in another clinical trial (using the investigational drug or a medical device) within 30 days before enrollment in this study
- Showed positive drug test results at the screening visit
- Did not agree to use a contraceptive method (male and female)
공부 계획
연구는 어떻게 설계됩니까?
디자인 세부사항
- 주 목적: 치료
- 할당: 무작위
- 중재 모델: 병렬 할당
- 마스킹: 하나의
무기와 개입
참가자 그룹 / 팔 |
개입 / 치료 |
|---|---|
|
실험적: TissueGene-C(Low dose)
Single intra-articular injection to the damaged knee joint at doses of 3.0 x 10^6 cells
|
3.0 x 10^6 cells
|
|
실험적: TissueGene-C(Medium dose)
Single intra-articular injection to the damaged knee joint at doses of 1.0 x 10^7 cells
|
1.0 x 10^7 cells
|
|
실험적: TissueGene-C(High dose)
Single intra-articular injection to the damaged knee joint at doses of 3.0 x 10^7 cells
|
3.0 x 10^7 cells
|
연구는 무엇을 측정합니까?
주요 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Number of Participants with Adverse Events after the administration of TissueGene-C
기간: 6 months
|
Number of Participants with Adverse Events after the administration of TissueGene-C
|
6 months
|
2차 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Changes in MRI scan
기간: before and 28 days, 3 months, and 6 months
|
Change in the MRI scan results after the administration of TissueGene-C
|
before and 28 days, 3 months, and 6 months
|
|
Change in the Knee Society Clinical Rating System(KSCRS) test results
기간: before and 7 days, 14 days, 21 days, 28 days, 3 months, and 6 months
|
Comparative Evaluation of knee exam
|
before and 7 days, 14 days, 21 days, 28 days, 3 months, and 6 months
|
|
Changes in WOMAC scores
기간: before and 7 days, 14 days, 21 days, 28 days, 3 months, and 6 months
|
Pain, stiffness, and physical function of the knee will be measured by the Western Ontario and McMaster Universities(WOMAC)
|
before and 7 days, 14 days, 21 days, 28 days, 3 months, and 6 months
|
|
Changes in 100 mm-VAS
기간: before and 7 days, 14 days, 21 days, 28 days, 3 months, and 6 months
|
Pain of the knee will be measured by the 100mm Visual Analogue Scale (VAS)
|
before and 7 days, 14 days, 21 days, 28 days, 3 months, and 6 months
|
|
Analysis of the TGF-β1 expression using Enzyme-linked Immunosorbent Assay(ELISA) and Polymerase Chain Reaction(PCR)
기간: before and 7 days, 14 days, 21 days, 28 days, 3 months, and 6 months
|
Analysis of the TGF-β1 expression using Enzyme-linked Immunosorbent Assay(ELISA) and Polymerase Chain Reaction(PCR)
|
before and 7 days, 14 days, 21 days, 28 days, 3 months, and 6 months
|
|
Replication-competent retrovirus test (RCR test)
기간: before and 7 days, 14 days, 21 days, 28 days, 3 months, and 6 months
|
Replication-competent retrovirus test (RCR test)
|
before and 7 days, 14 days, 21 days, 28 days, 3 months, and 6 months
|
공동 작업자 및 조사자
연구 기록 날짜
연구 주요 날짜
연구 시작
기본 완료 (실제)
연구 완료 (실제)
연구 등록 날짜
최초 제출
QC 기준을 충족하는 최초 제출
처음 게시됨 (추정)
연구 기록 업데이트
마지막 업데이트 게시됨 (실제)
QC 기준을 충족하는 마지막 업데이트 제출
마지막으로 확인됨
추가 정보
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .